<DOC>
	<DOCNO>NCT02173704</DOCNO>
	<brief_summary>Assess safety immunogenicity 3-dose schedule ( 2 , 4 , 6 month ) Novartis Meningococcal B recombinant vaccine follow booster 12 month concomitantly administer routine vaccine healthy infant Taiwan .</brief_summary>
	<brief_title>Safety Immunogenicity Novartis Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines Healthy Infants 2 Months Age Older , Taiwan .</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1. healthy 2month old infant ( 5589 day , inclusive ) , bear full term pregnancy estimate gestational age ≥ 37 week birth weight ≥ 2.5 kg ; 2. parent/legal guardian give write informed consent nature study explain ; 3. available visit schedule study ; 4. good health determine medical history , physical examination clinical judgment investigator . 1 . History meningococcal vaccine administration ; 2 . Prior vaccination Diphtheria , Tetanus , Pertussis ( acellular whole cell ) , Polio ( either Inactivated Oral ) , Haemophilus influenzae type b ( Hib ) , Pneumococcal , MMR varicella antigen ; 3 . Previous ascertain suspected disease cause N. meningitidis ; 4 . Household contact and/or intimate exposure individual laboratory confirm N. meningitidis ; 5 . History severe allergic reaction previous vaccination hypersensitivity vaccine component ; 6 . Significant acute chronic infection within previous 7 day body temperature high equal 38C degree within previous day ; 7 . Antibiotics within 6 day prior enrollment ; 8 . Any serious chronic progressive disease accord judgment investigator ( e.g. , neoplasm , insulin dependent diabetes mellitus Type I , cardiac disease , hepatic disease , progressive neurological disease seizure , either associate fever part underlie neurological disorder syndrome , autoimmune disease , HIV infection AIDS , blood dyscrasia diathesis , sign cardiac renal failure severe malnutrition ) ; 9 . Known suspected impairment/alteration immune system , immunosuppressive therapy , use systemic corticosteroid chronic use inhale highpotency corticosteroid since birth ; 10 . Receipt blood , blood product and/or plasma derivative parenteral immunoglobulin preparation ; 11 . Receipt , intent immunize vaccine ( ) ( exception rotavirus vaccine , influenza vaccine second HepB vaccine ) , within 28 day prior throughout study period . Furthermore , subject must receive HepB vaccine preferably 0 , 1 month age , second dose least 14 day prior study vaccination . Influenza vaccine administer least 14 day 14 day study vaccination ; Rotavirus vaccine may administer study per local practice . 12 . Participation another clinical trial since birth plan study ; 13 . Family member household member research staff ; 14 . Any condition , opinion investigator , might interfere evaluation study objective .</criteria>
	<gender>All</gender>
	<minimum_age>55 Days</minimum_age>
	<maximum_age>89 Days</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Infants</keyword>
	<keyword>Meningococcal B Recombinant Vaccine</keyword>
</DOC>